Arbor Trust Wealth Advisors LLC Acquires 90 Shares of Eli Lilly and Company (NYSE:LLY)

Arbor Trust Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,271 shares of the company’s stock after purchasing an additional 90 shares during the period. Arbor Trust Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $741,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. Morgan Stanley boosted its holdings in Eli Lilly and Company by 0.7% in the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after acquiring an additional 83,915 shares in the last quarter. Northern Trust Corp boosted its holdings in Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after acquiring an additional 355,317 shares in the last quarter. Norges Bank bought a new position in Eli Lilly and Company in the fourth quarter worth approximately $3,416,206,000. Finally, International Assets Investment Management LLC boosted its holdings in Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Truist Financial reiterated a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. BMO Capital Markets raised their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Barclays raised their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Morgan Stanley raised their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Finally, DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Price Performance

LLY stock traded down $4.21 during mid-day trading on Tuesday, hitting $746.56. 2,569,130 shares of the stock were exchanged, compared to its average volume of 3,085,273. The stock has a market capitalization of $709.35 billion, a price-to-earnings ratio of 128.34, a PEG ratio of 1.65 and a beta of 0.34. The business has a fifty day moving average price of $762.68 and a 200 day moving average price of $655.54. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 12 month low of $367.35 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.09 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 12.46 EPS for the current year.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.